explore -WSS

explore

author：entertainment 2025-10-02 18:46:29 - browse：36583

Adam's take main illustration — Molly Ferguson/STAT

Thoughts about Cytokinetics after Wednesday night’s financing announcement:

1. Management is raising $500 million at $51 per share, when the stock was at $45 per share before the aficamtem study readout in December. That’s shocking. Somehow, management has not only removed all the M&A premium from the stock, but much or most of aficamtem’s value, too.

2. Omecamtiv’s resurrection: Are you kidding me? No one thinks bringing back this heart failure drug is a good idea, except management. Making it worse, the terms of the Royalty Pharma loan are, again, shocking. All the risk is borne by Cytokinetics. Royalty, in fact, may do better if omecamtiv fails.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Snackable artificial intelligence, expert AI, and the pharma industry

explore

WSS

Cell therapy fails to slow type 1 diabetes, but safety is established

H5N1 bird flu virus started spreading in cows in Texas in December

Key Senate committee drafts bipartisan bill to stem drug shortages

Bird flu in milk supply is likely coming from asymptomatic cows

Ethical issues complicate the benefits of medical crowdfunding

Advances in CAR

knowledge

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

focus

Jerome Adams on the need for new antivirals for Covid

After traumatic brain injury, life support decisions can use more time

23andMe had bad news about my health. I wish a person had delivered it

How generative AI is inspiring dreams of a health data revolution

Novavax promises a turnaround & Lilly roils the obesity market

Cell therapy fails to slow type 1 diabetes, but safety is established

New air purifier tech could be key to improving indoor air quality

A rare thyroid diagnosis led to unexpected, all

23andMe had bad news about my health. I wish a person had delivered it

Medicaid rebukes states for mistakenly disenrolling children

focus

Melinda French Gates resigns from Gates Foundation

Amazon on where the company's health care bets are headed next

Covid hospitalizations on the rise, Humana says

How generative AI is inspiring dreams of a health data revolution

Element Biosciences CEO lays out genome sequencing strategy

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

explore

Wikipedia

Wikipedia

Wikipedia